87S Stock Chart & Stats
€24.50
<€0.01(0.05%)
At close: 4:00 PM EST
€24.50
<€0.01(0.05%)
Day’s Range― - ―
52-Week Range€9.11 - €32.21
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€21.71B
Enterprise Value€19.08K
Total Cash (Recent Filing)€4.30B
Total Debt (Recent Filing)€107.44M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 17, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding719,270,400
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.57Price Target Upside28.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.07
Revenue Forecast (FY)€70.85M
Bulls Say, Bears Say
Bulls Say
Balance Sheet / LiquidityA multi-billion dollar cash position and effectively zero debt provide durable runway to fund clinical programs, commercial build-out, and M&A or partnership optionality over the next 2–6 months. This reduces near-term refinancing and dilution risk while enabling strategic choices as data readouts arrive.
High Gross MarginA ~91% gross margin signals highly scalable product economics once therapies commercialize, allowing a path to profitability despite elevated R&D and SG&A. Strong product-level margins support durable operating leverage and better incremental returns on successful launches.
Pipeline Execution And Clinical SignalsRobust efficacy in a refractory population, preserved in JAK/TNF-experienced subsets, plus rapid enrollment across programs demonstrates operational execution and differentiation potential. These durable clinical signals and enrollment speed increase the probability of near-term regulatory and commercial catalysts.
Bears Say
Cash Burn / Weak Cash GenerationSustained negative operating and free cash flows imply ongoing funding needs to support development and commercialization. Even with strong liquidity today, continued high burn increases reliance on milestone monetizations, partnerships, or equity financing, which can dilute shareholders or constrain strategic flexibility.
Declining Revenue & Persistent Operating LossesSubstantial operating losses and material revenue decline indicate the company is not yet generating sustainable commercial profits. This structural weakness limits reinvestment capacity and increases dependency on successful launches or deal flow to convert cash reserves into recurring revenue.
Clinical Interpretability And Endpoint RiskOpen-label data can overstate efficacy; the planned randomized withdrawal primary endpoint may struggle to show separation given deep responses. These durable trial-design and interpretability risks could delay approvals, require additional studies, or weaken commercial positioning if confirmatory data fall short.
Roivant Sciences News
87S FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was €9.11 and its highest was €32.21 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is €21.71B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on May 20, 2026. The company reported €0.244 earnings per share for the quarter, beating the consensus estimate of -€0.253 by €0.497.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.25.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 719,270,400 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of €0.244 in its last earnings report, beating expectations of -€0.253. Following the earnings report the stock price went up 1.349%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in DE:87S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€31.57 (28.84% Upside)
€31.57 (28.84% Upside)
Blogger Sentiment
Bullish
DE:87S Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €189.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
196.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
87S Stock 12 Month Forecast
Average Price Target
€31.57
▲(28.84% Upside)